CliffBio
biologic

Elrexfio

elranatamab-bcmm

Loss of exclusivityAugust 2035projected — 12-year biologic exclusivity estimate
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameElrexfio
Active ingredientelranatamab-bcmm
Strength44MG/1.1ML (40MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2023
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Elrexfio patent cliff — loss of exclusivity August 2035 | CliffBio